A
Adaptive Biotechnologies
Decoding the Immune System
Seattle, WA
700+
About Adaptive Biotechnologies
Industry:
Immunomics/Diagnostics
Founded:
2009
Founders:
Chad Robins, Harlan Robins
Status:
Public (NASDAQ: ADPT)
Funding & Growth
Total Raised:
$500M+
Valuation:
$1.5B+ market cap
Stage:
Public
Key Investors:
Madrona Venture Group
Viking Global
Genentech
✓ Pros
- • Unique immune sequencing platform
- • Microsoft partnership
- • Seattle tech/biotech hub
- • Clinical and research applications
- • Strong science culture
✗ Cons
- • COVID test revenue decline
- • Market volatility
- • Competitive diagnostics market
- • Path to profitability